Prioritizing new medications to effectively preserve eyesight in the most common age-related and inherited retinal diseases, impacting over 420 million patients worldwide.

Pioneering "Stress Resilience-Enhancing Drugs" (SREDs) – a novel, multi-targeted therapeutic strategy, for the treatment of neurodegenerative conditions, to restore homeostasis among multiple cell types implicated in disease.